Treatment of Prolactinoma: First-Line Medical Approach
Prolactinoma is a prolactin-secreting adenoma managed primarily with medical therapy. First-line treatment targets both biochemical normalisation and tumour size control.
The principal aims are normalisation of serum prolactin and reduction of adenoma size. Response assessed at three months — based on both prolactin levels and tumour volume change — is a recognised predictor of long-term outcome.
Medical therapy with a dopamine agonist is the established first-line strategy. A preferred agent is selected based on its efficacy and tolerability profile; less commonly used alternatives are available depending on regional availability and patient factors. The complete regimen — including agent selection, monitoring schedule, and response criteria — is in the structured protocol below.
References
DOI: 10.1038/s41574-023-00886-5
- Cabergoline is the preferred dopamine agonist owing to its long half-life, high efficacy and good tolerability (strong).
- Cabergoline is used as primary medical therapy in patients with prolactinoma.
- Bromocriptine and quinagolide are less commonly used, depending on regional approval and availability.
- Dopamine agonist therapy is highly effective at lowering serum levels of prolactin, improving clinical consequences of hyperprolactinaemia and reducing adenoma size (strong).
- Normoprolactinaemia and tumour volume reduction of >25% after 3 months of cabergoline predicts long-term response.